With over 90% of drugs in clinical development failing to reach the market, a staggering $45B annual loss for the pharma and biotech industry, the need for more efficient processes is clear. Addressing this critical challenge, AI company QuantHealth has raised $2.0M in Series A funding.
QuantHealth's platform aims to accelerate and de-risk drug development by conducting patient-centric simulations. It allows partners to rapidly run thousands of clinical trial variations, optimizing designs and significantly increasing the probability of success. The company leverages a proprietary AI platform and one of the largest integrated datasets to predict patient-response to both approved and novel therapies.
